OH2 Injection in Solid Tumors

Melanoma Clinical Trial

Official title:

Open and Incremental Phase I Clinical Trial of Recombinant Human GM-CSF Type II Herpes Simplex Virus (OH2) Injection (Vero Cells) in the Treatment of Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04386967
• Other study ID #: OH2-I-ST-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 22, 2018
• Est. completion date: December 13, 2024

Study information

• Verified date: May 2023
• Source: Binhui Biopharmaceutical Co., Ltd.
• Contact: Jun Guo, PH.D
• Phone: 86-010-88140650
• Email: guoj307[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).

OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 13, 2024
• Est. primary completion date: March 13, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The non-operative stage III or stage IV malignant tumor patients with clear diagnosis by pathology and/ or cytology; breast cancer, gastrointestinal adenocarcinoma, liver cancer, cervical cancer, malignant melanoma, head and neck tumors, Priority inclusion in soft tissue sarcomas (mainly for melanoma patients at the dose extension phase).

2. The absence of a conventional effective treatment or treatment failure or recurrence by a conventional method.

3. Male or female patients, aged 18 = 75 years (including boundary value), general physical condition score ECOG 0 = 1, expected survival time more than 3 months.

4. Prior anti-tumor treatment (including endocrine, chemical/ radiotherapy,targeted therapy) was over 4 weeks (more than 6 weeks of discontinuation using nitroso-and mitomycin-based chemotherapy) and was recovered to grade 1 from the side effects of prior treatment.

5. Those who have undergone major surgery will have to undergo surgery for four weeks.

6. There is at least one measurable lesion that is suitable for intratumoral injection. According to RECIST version 1.1, it is determined that at least once the CT or MRI examination shows the tumor lesion, it is possible to measure the tumor focus. The measured tumor focus is defined as the longest diameter = 10 mm and the scanning thickness is not more than 5.0 mm. For lymph node lesions, the short diameter is = 15 mm.

7. There is no serious dysfunction of the main organs.

8. (a) WBC=3.0×109/L,ANC=2.0×109/L ,PLT=100×109/L,Hb=90 g/L; (b) BUN and Scr. were in the upper limit of 1.5 times of the normal value; (c) TBIL= 1.5 times the upper limit of the normal value. (d) ALT and AST = 2.5 times the upper limit of normal value; The value of patients with liver metastasis did not exceed 5 times the upper limit of normal value. (e) Coagulation function is normal (PT and APPT are within 1.5 times of the upper limit of normal value).

9. Female subjects and their spouses received effective contraceptives during and within 3 months of treatment.

10. Subjects with herpes in the reproductive organs needed three months after the end of herpes.

11. The informed consent was voluntarily signed and the expected compliance was good.

Exclusion Criteria:

1. Severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, severe infection, active digestive tract ulcer, abnormal immune function (including, but not limited to, rheumatoid arthritis, lupus erythematosus, Sjogren's syndrome, etc.).

2. History of primary grape-film melanoma or other malignant tumors in the 3 years prior to treatment. (use of combination drugs only)

3. Past or present immunodeficiency diseases. (use of combination drugs only)

4. Treated with PD-1/PD-L1 or PD-L2 monoantigens or inhibitors that have been used or used in the past. (use of combination drugs only)

5. Autoimmune diseases requiring systemic treatment (e.g. steroids or immunosuppressants) during the first 2 years of treatment, such as autoimmune pneumonia, glomerular nephritis, vasculitis and other symptoms of autoimmune diseases; Except for wind or child asthma. (use of combination drugs only)

6. Have uncontrolled primary or brain metastatic tumors.

7. Suffering from uncontrolled mental illness, infectious diseases.

8. The lesions cannot meet the requirements of injection capacity in the tumor body.

9. Pregnant or lactating women.

10. Other experimental therapies or antiviral therapy are used or are being used within 4 weeks of treatment.

11. Other clinical studies have been taken in the past 4 weeks.

12. Allergy to herpes virus and drug ingredients.

13. The researchers believe that there is any reason why the patient is not suitable to participate in this trial.

Related Conditions & MeSH terms

• Melanoma
• Neoplasms
• Solid Tumor

Intervention

Biological:
• OH2 injection
Oncolytic Type 2 Herpes Simplex Virus

Drug:
• Keytruda
Anti-PD-1 antibody

Locations

Country	Name	City	State
China	Peking University Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Binhui Biopharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Further evaluation of dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of OH2 in patients with solid tumors		12 months
Primary	The dose-limiting toxicity (DLT) of OH2 injection and Keytruda in patients with solid tumors		12 months
Primary	The maximum-tolerated dose (MTD) of OH2 injection in combination with Keytruda in patients with solid tumors		12 months
Secondary	The response rate of patients with solid tumors receiving OH2 injection monotherapy and OH2 injection in combination with Keytruda		12 months
Secondary	The biodistribution of OH2 injection as determined by the concentration of OH2 in blood, urine and feces of participating patients		12 months
Secondary	The immunogenicity of OH2 injection as determined by the detection of antibodies in response to OH2 and GM-CSF		12 months